statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Dr. Reddy's Laboratories (NYSE:RDY - Get Free Report) was upgraded by equities research analysts at StockNews.com from a "buy" rating to a "strong-buy" rating in a report issued on Friday.
Several...

StockNews.com Upgrades Dr. Reddy's Laboratories (NYSE:RDY) to "Strong-Buy"

Augustine Asset Management Inc. grew its position in Dr. Reddy's Laboratories Limited (NYSE:RDY - Free Report) by 3.5% during the 4th quarter, according to its most recent Form 13F filing with the...

Augustine Asset Management Inc. Has $3.52 Million Holdings in Dr. Reddy's Laboratories Limited (NYSE:RDY)

In recent trading, shares of Dr. Reddys Laboratories Ltd...

Dr. Reddy's Laboratories Reaches Analyst Target Price

Centhaquine is a first-of-its-kind resuscitative agent to treat hypovolemic shock by increasing stroke volume and cardiac output due to an increase in (preload) venous blood return to the heart and a...

Pharmazz Inc. and Dr. Reddy's Laboratories have entered into a licensing agreement to market Centhaquine (Lyfaquin) as a resuscitative agent for hypovolemic shock in India

Dr. Reddys Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY; hereafter referred to as Dr. Reddys), a global pharmaceutical company, announced the launch of Versavo...

Dr. Reddy's Laboratories launches Versavo (bevacizumab) in the UK

Dr. Reddys Laboratories Limited (NYSE:RDY  Free Report)  Investment analysts at Zacks Research dropped their Q3 2026 EPS estimates for Dr. Reddys Laboratories in a...

Research Analysts Offer Predictions for Dr. Reddy's Laboratories Limited's Q3 2026 Earnings (NYSE:RDY)

Dr. Reddys Laboratories Limited (NYSE:RDY  Free Report)  Research analysts at Zacks Research decreased their Q1 2026 earnings per share estimates for shares of Dr. Reddys...

Zacks Research Weighs in on Dr. Reddy's Laboratories Limited's Q1 2026 Earnings (NYSE:RDY)

Dr. Reddys Laboratories Limited (NYSE:RDY  Free Report)  Equities research analysts at Zacks Research increased their FY2024 earnings per share estimates for shares of Dr...

FY2024 EPS Estimates for Dr. Reddy's Laboratories Limited Increased by Zacks Research (NYSE:RDY)

Dr. Reddys Laboratories Limited (NYSE:RDY  Free Report)  Zacks Research reduced their Q1 2026 EPS estimates for shares of Dr. Reddys Laboratories in a note issued to...

Q1 2026 EPS Estimates for Dr. Reddy's Laboratories Limited Lowered by Analyst (NYSE:RDY)

Quantbot Technologies LP reduced its stake in Dr. Reddys Laboratories Limited (NYSE:RDY  Free Report) by 94.2% during the third quarter, according to the company in its most recent Form...

Quantbot Technologies LP Sells 9,736 Shares of Dr. Reddy's Laboratories Limited (NYSE:RDY)

Dr. Reddy's Laboratories Ltd. engages in the manufacture and marketing of pharmaceutical products. It operates through the following segments: Global Generics, Pharmaceutical Services & Active Ingredients, Proprietary Products, and Others. The Global Generics segment consists of manufacturing and marketing of prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name or as generic finished dosages with therapeutic equivalence to branded formulations. The Pharmaceutical Services & Active Ingredients segment is comprised of manufacturing and marketing of active pharmaceutical ingredients and intermediates, also known as API, which are the principal ingredients for finished pharmaceutical products. The Proprietary Products segment focuses on research and development of differentiated formulations. The Others segment includes the operations of the subsidiary of the company. The company was founded by Kallam Anji Reddy on February 24, 1984 and is headquartered in Hyderabad, India.

Volume	132,242.00
52-Wk High	$77.72
52-Wk Low	$53.12

RDY Dr. Reddy's Laboratories Ltd.

About

Feed

News

Sentiment

Earnings

Fundamentals